Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
DeLucas LJ
It displayed greater than 23-fold selective inhibition of the breast CSC-like cell line (HMLE_sh_Ecad) over the isogenic control cell line (HMLE_sh_GFP)
a with a Kd of 0
on the production of inflammatory mediators by rheumatoid synovial fibroblasts
58(6):916-23
DCC-2036 t N-oxide DeLucas LJDCC 2036, is an orally bioavailable small molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC 2036 binds to and inhibits the Bcr Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand dependent and ligand independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine